Glucocorticoids are central to treating inflammatory and immune disorders. These steroids, however, profoundly impact the skeleton, particularly when administered for prolonged periods. In fact, high-dose glucocorticoid therapy is almost universally associated with bone loss, prompting among the most common forms of crippling osteoporosis. Despite the frequency and severity of glucocorticoid-induced osteoporosis, its treatment is less than satisfactory, suggesting that its pathogenesis is incompletely understood.
Net bone mass represents the relative activities of osteoblasts and osteoclasts and there is little question that glucocorticoids suppress the bone-forming cells, in vivo, via a process involving accelerated apoptosis (Weinstein 2001; Weinstein, Jilka, Parfitt, et al. 1998). Surprisingly, however, addition of glucocorticoids to cultures of osteoprogenitor cells actually increases their capacity to form mineralized bone nodules (Aubin 1999; Purpura, Aubin, and Zandstra 2004). This paradox raises the possibility that glucocorticoid suppression of bone formation, in vivo, reflects, at least in part, the steroid’s targeting intermediary cells, which in turn inhibit the osteoblast.
Bone remodeling is an ever-occuring event in mammals which is characterized by tethering of osteoclast and osteoblast function. The process is initiated by osteoclasts (OCs) resorbing a packet of bone, which in turn leads to osteoblasts being recruited to the site of resorption. This process establishes that osteoclastic bone resorption, in some manner, promotes osteoblastic bone formation at the same location. Consequently, pathologically or pharmacologically inhibited resorption eventuates in arrested osteoblast activity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aubin, J.E. 1999. Osteoprogenitor cell frequency in rat bone marrow stromal populations: role for heterotypic cell-cell interactions in osteoblast differentiation. J Cell Biochem 72: 396–410.
Chellaiah, M.A., N. Soga, S. Swanson, S. McAllister, U. Alvarez, D. Wang, S.F. Dowdy, and K.A. Hruska. 2000. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem 275: 11993–12002.
Dempster, D.W. 1989. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4: 137–141.
Faccio, R., S.L. Teitelbaum, K. Fujikawa, J.C. Chappel, A. Zallone, V.L. Tybulewicz, F.P. Ross, and W. Swat, 2005. Vav3 regulates osteoclast function and bone mass. Nat Med 11: 284–290.
Hirayama, T., A. Sabokbar, and N.A. Athanasou, 2002. Effect of corticosteroids on human osteoclast formation and activity. J Endocrinol 175: 155–163.
Hofbauer, L.C., F. Gori, B.L. Riggs, D.L. Lacey, C.R. Dunstan, T.C. Spelsberg, and S. Khosla, 1999. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinol 140: 4382–4389.
Kim, H.-J., H. Zhao, H. Kitaura, S. Bhattacharyya, J.A. Brewer, L.J. Muglia, F.P. Ross, and S.L. Teitelbaum. 2006. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116: 2152–2160.
Korhonen, M., H. Zhao, R. Faccio, F.P. Ross, T.M. Hopkins, J.A. Cancelas, S.L. Teitelbaum, and D.A. Williams. 2005. Rac1 and Rac2 GTPases play distinct roles and are essential for full osteoclast differentiation. ASH Annual Meeting Abstracts 106: 67.
Manolagas, S.C., and R.S. Weinstein. 1999. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14: 1061–1066.
Prummel, M.F., W.M. Wiersinga, P. Lips, G.T. Sanders, and H.P. Sauerwein. 1991. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 72: 382–386.
Purpura, K.A., J.E. Aubin, and P.W. Zandstra. 2004. Sustained in vitro expansion of bone progenitors is cell density dependent. Stem Cells 22: 39–50.
Rickard, D.J., T.A. Sullivan, B.J. Shenker, P.S. Leboy, and I. Kazhdan. 1994. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev Biol 161: 218–228.
Rubin, J., D.M. Biskobing, L. Jadhav, D. Fan, M.S. Nanes, S. Perkins, and X. Fan. 1998. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinol 139: 1006–1012.
Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science 289: 1504–1508.
Weinstein, R.S. 2001. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2: 65–73.
Weinstein, R.S., R.L. Jilka, A.M. Parfitt, and S.C. Manolagas. 1998. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 102: 274–282.
Weinstein, R.S., J.-R. Chen, C.C. Powers, S.A. Stewart, R.D. Landes, T. Bellido, R.L. Jilka, A.M. Parfitt, and S.C. Manolagas. 2002. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109: 1041–1048.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this paper
Cite this paper
Kim, HJ. et al. (2007). Dexamethsone Suppresses Bone Formation via the Osteoclast. In: Choi, Y. (eds) Osteoimmunology. Advances in Experimental Medicine and Biology, vol 602. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-72009-8_5
Download citation
DOI: https://doi.org/10.1007/978-0-387-72009-8_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-72008-1
Online ISBN: 978-0-387-72009-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)